Short-Term Versus Long-Term Efficacy of Endoscopic Sleeve Gastroplasty in 8880 Obese Patients: A Systematic Review and Meta-Analysis.

Diabetes Obes MetabJun 18, 2026 (epub)
Clinical ResearchGastroenterologyOpen access

Mohammed Barghash, Matthew Riad, Yasser Khalil et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review and meta-analysis evaluated the efficacy of endoscopic sleeve gastroplasty (ESG) in 8880 obese patients, focusing on weight loss and metabolic outcomes over short- and long-term follow-up. The study found that % total body weight loss (%TBWL) increased from 8.66% at 1 month to 17.88% at 1 year, with a modest decline to 15.67% at 3 years.

Key findings

  • %TBWL increased from 8.66% at 1 month to 17.88% at 1 year.
  • Long-term %TBWL declined to 15.67% at 3 years.
  • Remission rates were 62% for type 2 diabetes and 43% for both hypertension and dyslipidaemia.
  • Weight regain occurred in 6% of patients.

Why it matters

Understanding the durability of weight loss and metabolic improvements following ESG is crucial for clinicians managing obesity. This evidence supports ESG as a viable option for long-term weight management and metabolic health.

Source

PubMed · PMID 42315493Free full text on PubMed Central

Published in Diabetes Obes Metab. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Gastroenterology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.